Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Omnicell, Inc. is a healthcare technology company that designs and provides medication management solutions and services primarily for hospitals, health systems, and retail and specialty pharmacies. The company operates within the healthcare technology and medical devices industries, with a focus on improving medication safety, operational efficiency, and clinical outcomes across the medication use process.
The company’s core revenue drivers include automated dispensing cabinets, pharmacy automation systems, medication adherence solutions, and associated software and services. Omnicell serves acute care hospitals, health systems, long-term care facilities, and pharmacy providers, positioning itself as an end-to-end medication management partner. Founded in 1992, Omnicell initially focused on automated dispensing technology and expanded over time through internal development and acquisitions into pharmacy automation, analytics, and adherence-focused solutions.
Business Operations
Omnicell generates revenue through the sale of hardware, software licenses, subscriptions, and professional services. Its operations are organized around major business segments that include Medication Dispensing Systems, Pharmacy Automation, and Medication Adherence Solutions, which collectively support inpatient, outpatient, and post-acute care settings. Recurring revenue from software subscriptions, SaaS offerings, and service contracts represents an increasing portion of the company’s revenue mix.
The company operates primarily in the United States with additional international sales and service activities. Omnicell controls proprietary automation technologies, software platforms, and analytics capabilities that integrate with electronic health records and pharmacy information systems. Its operations include wholly owned subsidiaries and long-term commercial relationships with healthcare providers, group purchasing organizations, and technology partners.
Strategic Position & Investments
Omnicell’s strategic direction emphasizes transitioning healthcare providers toward a more automated, data-driven, and outcomes-focused medication management model. Growth initiatives have centered on expanding its SaaS-based platforms, increasing recurring revenue, and deepening customer relationships through enterprise-wide solutions rather than standalone products.
The company has pursued strategic acquisitions to broaden its technology portfolio and customer reach, including EnlivenHealth, which strengthened Omnicell’s position in medication adherence and patient engagement solutions. Omnicell also continues to invest in cloud-based analytics, interoperability, and emerging pharmacy automation technologies to support health system efficiency, cost reduction, and patient safety.
Geographic Footprint
Omnicell is headquartered in North America, with its corporate headquarters located in the United States. The majority of its revenue is generated from U.S.-based healthcare providers, reflecting the company’s strong penetration in domestic hospital and pharmacy markets.
Internationally, Omnicell maintains a presence across Europe, Asia-Pacific, and other select global markets through direct sales, distribution partners, and service operations. While international revenue represents a smaller portion of total revenue compared to the United States, the company maintains strategic international operations to support multinational healthcare organizations and long-term growth opportunities.
Leadership & Governance
Omnicell is led by an executive team with experience across healthcare technology, medical devices, and enterprise software. The leadership team emphasizes a strategic vision focused on automation, digital transformation, and measurable clinical and operational outcomes for healthcare providers.
Key executives include:
- Randall A. Lipps – Chairman of the Board, President, and Chief Executive Officer
- Peter R. Hennen – Chief Financial Officer
- Mark L. Berry – Executive Vice President and Chief Operating Officer
- Sanjeev K. Ahuja – Executive Vice President and Chief Commercial Officer
- Praveen Raja – Senior Vice President and Chief Technology Officer
The company is governed by a board of directors that provides oversight on strategy, risk management, and long-term value creation, with a governance framework aligned with U.S. public company standards.